Ranbezolid

Ranbezolid is an oxazolidinone antibiotic that is currently under development. It is a synthetic antibacterial agent that has demonstrated significant in vitro and in vivo activity against a broad spectrum of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

Mechanism of Action

Ranbezolid inhibits protein synthesis in bacteria by binding to the ribosome and blocking the formation of a functional 70S-initiation complex. This is a critical step in the bacterial translation process and is therefore a point of attack for several antibiotic classes.

Pharmacokinetics

Ranbezolid is well absorbed after oral administration and has a bioavailability of approximately 90%. It is extensively distributed to tissues and fluids, including lung tissue and cerebrospinal fluid. The drug is primarily metabolized by the liver and excreted in the urine and feces.

Clinical Trials

Ranbezolid has undergone Phase 2 clinical trials for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including MRSA and VRE. The results of these trials have shown that ranbezolid is well tolerated and effective in the treatment of these infections.

Side Effects

The most common side effects of ranbezolid include nausea, vomiting, diarrhea, and headache. Less common side effects include dizziness, insomnia, and rash.

See Also

• Oxazolidinone
• Antibiotic
• Methicillin-resistant Staphylococcus aureus
• Vancomycin-resistant enterococci

Ranbezolid

• 
  Ranbezolid structure